---
title: "Arbutus Pharma | 8-K: FY2026 Q1 Revenue: USD 179.13 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286252409.md"
datetime: "2026-05-13T11:33:12.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286252409.md)
  - [en](https://longbridge.com/en/news/286252409.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286252409.md)
---

# Arbutus Pharma | 8-K: FY2026 Q1 Revenue: USD 179.13 M

Revenue: As of FY2026 Q1, the actual value is USD 179.13 M.

EPS: As of FY2026 Q1, the actual value is USD 0.87.

EBIT: As of FY2026 Q1, the actual value is USD 168.11 M.

#### Revenue

Total revenue for the first quarter ended March 31, 2026, was $179.1 million, a significant increase from $1.8 million for the same period in 2025 . This $177.4 million increase was primarily due to license revenue from Genevant related to Arbutus Biopharma Corporation’s portion of the Noncontingent Settlement Payment . Specifically, license revenue from Genevant was $178,741 thousand in Q1 2026, compared to $0 in Q1 2025 . Collaborations and licenses revenue was $204 thousand in Q1 2026, down from $1,316 thousand in Q1 2025 . Non-cash royalty revenue was $181 thousand in Q1 2026, compared to $448 thousand in Q1 2025 .

#### Operating Expenses

Research and development expenses decreased to $4.1 million for Q1 2026, from $9.0 million in Q1 2025, a reduction of $4.8 million . This decrease was mainly attributed to cost savings from workforce reduction, discontinuation of in-house scientific research, and lower clinical trial costs . General and administrative expenses slightly increased to $5.9 million in Q1 2026, from $5.8 million in Q1 2025, primarily due to higher legal fees from the Moderna settlement, partially offset by cost-cutting efforts . Restructuring costs were $0 in Q1 2026, a decrease from $12.4 million in Q1 2025 . Total operating expenses were $10,218 thousand in Q1 2026, down from $27,463 thousand in Q1 2025 .

#### Net Income/Loss

Arbutus Biopharma Corporation reported a net income of $169.7 million for Q1 2026, a substantial improvement from a net loss of - $24.5 million in Q1 2025 . Income from operations was $168,908 thousand in Q1 2026, compared to a loss from operations of - $25,699 thousand in Q1 2025 .

#### Cash Flow and Financial Position

As of March 31, 2026, cash, cash equivalents, and marketable securities totaled $95.2 million, an increase from $91.5 million as of December 31, 2025 . Net cash used in operating activities during Q1 2026 was - $8.1 million, which included one-time payments related to restructuring efforts . This compares to net cash used in operating activities of - $13,391 thousand in Q1 2025 . The company also received $11.5 million in proceeds from the exercise of stock options during Q1 2026 . Net cash provided by investing activities was $2,199 thousand in Q1 2026, and net cash provided by financing activities was $11,619 thousand .

#### Unique Metrics and Outlook

Arbutus Biopharma Corporation expects to receive an estimated $178.7 million of the Noncontingent Settlement Payment from Moderna in July 2026, as part of a $950 million upfront settlement . An additional $1.3 billion is contingent upon an appellate ruling regarding patent infringement claims . The U.S. Food and Drug Administration (FDA) granted Fast Track designation to imdusiran for the treatment of chronic hepatitis B in April 2026, which has the potential to facilitate development and accelerate FDA review . This designation may offer benefits such as earlier and more frequent meetings with the FDA and potential eligibility for Accelerated Approval or Priority Review .

### Related Stocks

- [ABUS.US](https://longbridge.com/en/quote/ABUS.US.md)

## Related News & Research

- [The Home Depot Announces First Quarter Fiscal 2026 Results; Reaffirms Fiscal 2026 Guidance | HD Stock News](https://longbridge.com/en/news/286890512.md)
- [ONWARD Medical to Announce First Quarter 2026 Results on May 26, 2026 | ONWRY Stock News](https://longbridge.com/en/news/286858298.md)
- [Correction: NextNRG to Host First Quarter 2026 Financial Results Conference Call on May 18, 2026 at 9:00 a.m. ET | NXXT Stock News](https://longbridge.com/en/news/286673001.md)
- [Keysight Technologies Reports Second Quarter 2026 Results | KEYS Stock News](https://longbridge.com/en/news/286959830.md)
- [Prairie Operating Co. Announces First Quarter 2026 Results and Reaffirms 2026 Guidance | PROP Stock News](https://longbridge.com/en/news/286463109.md)